CICC Rates Merck (MRK) buy, $138 Price Target
CICC maintains its buy rating on Merck with a $138 price target, a 7.26% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
CICC rated Merck & Co., Inc. ($MRK) "buy" with a $138 price target on June 24, 2026.
Since the rating, $MRK is up 4.0% after 1 week, up 8.7% after 1 month and up 21.7% to date (from the $119.89 close on Jun 24, 2026).
MRK
Merck & Co., Inc.
Key Points
- CICC reiterated its buy rating on Merck & Co., Inc. (NYSE:MRK) with a price target of $138 on June 24, 2026.
- CICC's $138 price target implies 7.26% upside from Merck & Co., Inc.'s ($MRK) current $128.66 share price.
- Merck shares traded near $119.6 on Wednesday, with a market cap of $285.2 billion and a forward P/E of 12.06.
- Insider buying activity was noted with multiple insiders purchasing shares on May 29, 2026.
Get $MRK trade alerts by text
We text you when insiders, Congress or big funds trade $MRK. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Merck & Co., Inc. alert may contain errors. Disclosures
CICC reiterated its buy rating on Merck & Co., Inc. (NYSE:MRK) on June 24, 2026, setting a price target of $138. This action underscores the firm's confidence in Merck's prospects.
CICC vs. the S&P 500
Hypothetical returns from CICC's disclosed trades, not real profit or advice. How we model this.
Merck & Co., Inc. Stock Down 11.4%
Shares of NYSE:MRK traded near $119.6 on Wednesday. Merck & Co., Inc. has a market cap of approximately $285.2 billion, with a P/E ratio of 32.53 and a forward P/E of 12.06. The stock's beta is a low 0.218, indicating less volatility compared to the market. Merck's 52-week range spans from $76.66 to $125.14, with a 50-day moving average of $115.69 and a 200-day moving average of $105.39.
$MRK price target
Merck & Co., Inc. daily closes and this analyst's $138 target. Not advice.
Recent Earnings
Merck reported revenue of $65.77 billion, reflecting a growth of 4.9%. The company's net margin stands at 13.6%, with a return on equity of 18.9%. Merck's next earnings report is scheduled for August 4, 2026.
Insider Buying and Selling at Merck & Co., Inc.
On May 29, 2026, several insiders, including Kathy Warden, Paul Rothman, and Christine Seidman, each purchased 1,853 shares at an average price of $118.72. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 24, 2026, CICC reiterated its buy rating on Merck & Co., Inc. with a $138 price target. Earlier, Wells Fargo and UBS maintained their buy ratings with targets of $145. JP Morgan also maintained a buy rating, setting a target of $135.
About Merck & Co., Inc.
Merck & Co., Inc., headquartered in Rahway, New Jersey, is a global healthcare company. It develops pharmaceuticals for human and animal health, including well-known brands like Keytruda and Gardasil. Merck also engages in strategic collaborations and has a significant presence in drug manufacturing, employing around 73,000 people.
Bottom Line
CICC's reiteration of a buy rating with a $138 target price reflects continued optimism about Merck's future performance. Investors often track analyst ratings to gauge market sentiment, but it's important to remember these are forward-looking opinions. As always, actual investment decisions should consider a range of factors.
Related Filing Alerts
Source: CICC's rating change on $MRK (Jun 24, 2026). Written by software, not financial advice. How we make alerts